NX-2127

ASH 2022 – pirtobrutinib leads the post-Imbruvica charge
EP Vantage
Wed, 12/14/22 - 10:18 am
ASH 2022
Eli Lilly
BeiGene
Nurix Therapeutics
Brukinsa
pirtobrutinib
NX-2127